Senseonics Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a U.S.-listed medtech company trading on NASDAQ under the ticker SENS. Headquartered in Germantown, Maryland, United States, the company focuses on the development, manufacturing, and commercialization of long-term implantable continuous glucose monitoring (CGM) systems for people living with diabetes. Its core franchise is the Eversense family, a differentiated CGM platform built around an implantable sensor placed under the skin, paired with a wearable transmitter and mobile app. This design sets Senseonics apart from conventional external CGM systems and is central to its investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)) From a corporate history standpoint, Senseonics has been built around proprietary implantable sensor technology designed to improve glucose monitoring convenience and reduce the frequency of sensor replacement. The company is organized as a Delaware corporation and has long operated from its Maryland base. Over time, it expanded its commercial footprint through successive Eversense iterations, including Eversense E3, which was FDA-approved in February 2022, and Eversense 365, which was cleared for sale in the United States in September 2024. Those milestones matter because they show the company’s move from a single-product innovator toward a broader commercial diabetes-technology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000155837025006983/sens-20250331x10q.htm?utm_source=openai)) Operationally, Senseonics is still largely a focused, one-platform company centered on diabetes care. Its business includes development, manufacturing, and commercialization of implantable CGM systems, as well as future-generation programs such as Gemini and Freedom referenced in regulatory filings. The company uses a hybrid commercial model, combining direct commercialization with third-party distribution partnerships in markets where those partners already have sales infrastructure and healthcare relationships. That structure allows Senseonics to pursue the U.S. market while also maintaining a presence in select overseas markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)) In competitive terms, Senseonics occupies a specialized niche within the broader CGM market. Its key differentiator is the long duration of its implantable sensors and the convenience proposition associated with fewer sensor changes. The flip side is that adoption depends heavily on insurance coverage, physician awareness, and access to trained inserters. In other words, the technology is differentiated, but commercialization remains execution-sensitive. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)) Recent developments are particularly important for investors. In 2026, Senseonics completed the transition of U.S. commercial responsibility for Eversense back to the company from Ascensia, meaning the company now captures the U.S. product revenue directly. Management has also continued to emphasize the rollout of Eversense 365, the expansion of payer coverage, and further commercialization in Europe and EMEA. These are meaningful near-term catalysts because they influence revenue mix, operating leverage, and the sustainability of growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))